Corbus director sells 2,000 shares in planned trade
CRBP director Ben Yong reported a small, pre-planned sale of 2,000 shares, retaining 9,383 shares including unvested RSUs.
Rhea-AI Filing Summary
Corbus Pharmaceuticals Holdings, Inc. (CRBP) director Ben Yong sold 2,000 shares of common stock on September 14, 2026 in an open-market transaction at a weighted average price of $7.84 per share, under a Rule 10b5-1 trading plan adopted on June 12, 2026. Following the sale, he held 9,383 shares in total, including 3,800 unvested RSUs subject to vesting schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,000 shares
Net Sell
1 txn
Insider
Ben Yong
Role
Director
Sold
2,000 shs ($16K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.0001 per share F1, F2, F3 | 2,000 | $7.8415 | $16K |
Holdings After Transaction:
Common Stock, par value $0.0001 per share — 9,383 shares (Direct)
Footnotes (3)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.
- F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 to $7.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. This amount includes 3,800 unvested RSUs subject to each grant's vesting schedule as previously reported.
Key Figures
Shares sold: 2,000 shares
Weighted average sale price: $7.84 per share
Approximate transaction value: $15,683
+2 more
5 metrics
Shares sold
2,000 shares
Common stock sale reported for September 14, 2026
Weighted average sale price
$7.84 per share
Sale prices ranged from $7.80 to $7.90
Approximate transaction value
$15,683
2,000 shares sold at $7.84 weighted average price
Shares owned after transaction
9,383 shares
Total beneficial ownership following the September 14, 2026 sale
Unvested RSUs included in holdings
3,800 RSUs
Unvested restricted stock units included in post-transaction total
Key Terms
Rule 10b5-1 trading plan, weighted average price, RSUs, unvested RSUs
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
RSUs financial
"This amount includes 3,800 unvested RSUs subject to each grant's vesting schedule"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
unvested RSUs financial
"This amount includes 3,800 unvested RSUs subject to each grant's vesting schedule"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CRBP director Ben Yong report on this Form 4?
Ben Yong reported a sale of 2,000 shares of Corbus Pharmaceuticals common stock on September 14, 2026, classified as an open-market or private sale of non-derivative common stock.
Was the CRBP insider sale by Ben Yong made under a Rule 10b5-1 trading plan?
Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan that Ben Yong adopted on June 12, 2026, indicating the trade was pre-arranged under that plan.
How large is Ben Yong’s reported CRBP sale in dollar terms?
Using the disclosed weighted average price of $7.84 per share and 2,000 shares sold, the transaction size is approximately $15,683 in total value.
What portion of Ben Yong’s CRBP holdings are unvested RSUs?
Out of Ben Yong’s total 9,383 shares reported after the transaction, 3,800 are unvested RSUs, which remain subject to each grant’s vesting schedule as previously reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.
